[New alternatives for the treatment of antiphospholipid syndrome. A literature review].
For years the mainstay of antiphospholipid syndrome treatment has been anticoagulation and antiplatelet therapy, but the autoimmune nature of the disease, and complications of these therapies, created the need to develop new therapeutic strategies. New therapeutic alternatives inhibit at different levels, the cascade of events leading to the pro-thrombotic state characteristic of the antiphospholipid syndrome. We conducted a literature review of these new treatments, focusing on the pathophysiological bases that support them and their possible clinical applications.
Sebastián
S
Ibáñez
Mirentxu
M
Iruretagoyena
Miguel A
MA
Gutiérrez
D000376:Agmatine / Q000031:analogs & derivatives / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use; D016736:Antiphospholipid Syndrome / Q000188:drug therapy* / Q000503:physiopathology; D004151:Dipeptides / Q000627:therapeutic use; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D006886:Hydroxychloroquine / Q000627:therapeutic use; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D000069283:Rituximab; D013927:Thrombosis / Q000188:drug therapy
D058846:Antibodies, Monoclonal, Murine-Derived; D004151:Dipeptides; D005938:Glucocorticoids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; C061222:estatin B; C061221:estatin A; D000069283:Rituximab; D006886:Hydroxychloroquine; D000376:Agmatine